Booster vaccination after neonatal priming with acellular pertussis vaccine. 2010

Markus Knuf, and Heinz-Josef Schmitt, and Jeanne-Marie Jacquet, and Alix Collard, and Dorothee Kieninger, and Claudius U Meyer, and Claire-Anne Siegrist, and Fred Zepp
Department of Pediatrics, Johannes Gutenberg-University, Mainz, Germany. knuf@kinder.klinik.uni-mainz.de

After a birth dose of acellular pertussis (aP) and diphtheria (DT)aP-hepatitis B virus (HBV)-inactivated polio vaccine (IPV)/Haemophilus influenza type b (Hib) at 2, 4, and 6 months, a booster dose of DTaP-HBV-IPV/Hib at 12 to 23 months induced strong anti-pertussis booster responses. Thus, neonatal aP priming did not lead to immune tolerance to pertussis antigens. However, it elicited bystander interference on HBV, Hib, and diphtheria responses.

UI MeSH Term Description Entries
D007117 Immunization, Secondary Any immunization following a primary immunization and involving exposure to the same or a closely related antigen. Immunization, Booster,Revaccination,Secondary Immunization,Booster Immunization,Booster Immunizations,Immunizations, Booster,Immunizations, Secondary,Revaccinations,Secondary Immunizations
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D010567 Pertussis Vaccine A suspension of killed Bordetella pertussis organisms, used for immunization against pertussis (WHOOPING COUGH). It is generally used in a mixture with diphtheria and tetanus toxoids (DTP). There is an acellular pertussis vaccine prepared from the purified antigenic components of Bordetella pertussis, which causes fewer adverse reactions than whole-cell vaccine and, like the whole-cell vaccine, is generally used in a mixture with diphtheria and tetanus toxoids. (From Dorland, 28th ed) Vaccine, Pertussis
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014611 Vaccination Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis. Immunization, Active,Active Immunization,Active Immunizations,Immunizations, Active,Vaccinations
D014917 Whooping Cough A respiratory infection caused by BORDETELLA PERTUSSIS and characterized by paroxysmal coughing ending in a prolonged crowing intake of breath. Pertussis,Bordetella pertussis Infection, Respiratory,Cough, Whooping,Pertusses

Related Publications

Markus Knuf, and Heinz-Josef Schmitt, and Jeanne-Marie Jacquet, and Alix Collard, and Dorothee Kieninger, and Claudius U Meyer, and Claire-Anne Siegrist, and Fred Zepp
April 1993, Pediatrics,
Markus Knuf, and Heinz-Josef Schmitt, and Jeanne-Marie Jacquet, and Alix Collard, and Dorothee Kieninger, and Claudius U Meyer, and Claire-Anne Siegrist, and Fred Zepp
June 2008, The Pediatric infectious disease journal,
Markus Knuf, and Heinz-Josef Schmitt, and Jeanne-Marie Jacquet, and Alix Collard, and Dorothee Kieninger, and Claudius U Meyer, and Claire-Anne Siegrist, and Fred Zepp
April 2009, Vaccine,
Markus Knuf, and Heinz-Josef Schmitt, and Jeanne-Marie Jacquet, and Alix Collard, and Dorothee Kieninger, and Claudius U Meyer, and Claire-Anne Siegrist, and Fred Zepp
February 2013, The New England journal of medicine,
Markus Knuf, and Heinz-Josef Schmitt, and Jeanne-Marie Jacquet, and Alix Collard, and Dorothee Kieninger, and Claudius U Meyer, and Claire-Anne Siegrist, and Fred Zepp
November 2011, Vaccine,
Markus Knuf, and Heinz-Josef Schmitt, and Jeanne-Marie Jacquet, and Alix Collard, and Dorothee Kieninger, and Claudius U Meyer, and Claire-Anne Siegrist, and Fred Zepp
January 2016, Vaccine,
Markus Knuf, and Heinz-Josef Schmitt, and Jeanne-Marie Jacquet, and Alix Collard, and Dorothee Kieninger, and Claudius U Meyer, and Claire-Anne Siegrist, and Fred Zepp
September 2013, Clinical and vaccine immunology : CVI,
Markus Knuf, and Heinz-Josef Schmitt, and Jeanne-Marie Jacquet, and Alix Collard, and Dorothee Kieninger, and Claudius U Meyer, and Claire-Anne Siegrist, and Fred Zepp
July 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Markus Knuf, and Heinz-Josef Schmitt, and Jeanne-Marie Jacquet, and Alix Collard, and Dorothee Kieninger, and Claudius U Meyer, and Claire-Anne Siegrist, and Fred Zepp
April 1991, The Pediatric infectious disease journal,
Markus Knuf, and Heinz-Josef Schmitt, and Jeanne-Marie Jacquet, and Alix Collard, and Dorothee Kieninger, and Claudius U Meyer, and Claire-Anne Siegrist, and Fred Zepp
April 2006, Pediatrics,
Copied contents to your clipboard!